EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-18	180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-30	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)	2020-05-14
Laurus	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	213038	ANDA	Laurus Labs Limited	42385-929-31	30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)	2020-05-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for the active pharmaceutical ingredients (APIs) Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate. These drugs are integral components of fixed-dose combination (FDC) antiretroviral therapies used in the treatment of HIV/AIDS. The analysis identifies key manufacturers, their production capacities, patent landscapes, and regulatory approvals that impact supply stability and market access.

Key Manufacturers and Production Capacities

The production of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate is concentrated among a limited number of API manufacturers, primarily located in India and China. These manufacturers often possess the necessary technical expertise and economies of scale to meet global demand for these essential medicines.

Table 1: Major API Manufacturers and Geographic Distribution

API	Key Manufacturers (Examples)	Primary Manufacturing Regions	Estimated Annual Capacity (Metric Tons)	Notes
Efavirenz	Cipla, Mylan, Aurobindo, Ipca Laboratories, Zhejiang NHU	India, China	> 100	High volume production driven by generic demand.
Lamivudine	Hetero Drugs, Gland Pharma, Strides Pharma Science, Apotex	India, China	> 150	Significant production for FDCs and monotherapy.
Tenofovir Disoproxil Fumarate (TDF)	Hetero Drugs, Mylan, Aurobindo, Aarti Industries, Apicore	India, China	> 200	High demand due to widespread use in combination.

Note: Estimated annual capacities are based on publicly available data and industry reports, which may vary.

Cipla Limited

Cipla is a significant supplier of Efavirenz. The company has a robust API manufacturing infrastructure, with multiple facilities accredited by major regulatory bodies. Cipla's capacity for Efavirenz is a key factor in its availability for generic formulations.

Hetero Drugs Limited

Hetero Drugs is a major producer of both Lamivudine and Tenofovir Disoproxil Fumarate. The company operates large-scale manufacturing sites in India that adhere to Good Manufacturing Practices (GMP). Hetero's integrated manufacturing capabilities contribute to cost-effectiveness and supply chain reliability for these APIs.

Mylan N.V. (now Viatris)

Mylan, now part of Viatris, has historically been a substantial supplier of Efavirenz and Tenofovir Disoproxil Fumarate. Viatris maintains a global manufacturing network, enabling it to serve diverse markets.

Aurobindo Pharma Limited

Aurobindo Pharma is another prominent Indian manufacturer with significant production capacity for Efavirenz and Tenofovir Disoproxil Fumarate. The company's extensive portfolio of APIs supports its position in the global generics market.

Aarti Industries Limited

Aarti Industries specializes in benzene-based intermediates and is a key producer of Tenofovir Disoproxil Fumarate. Its expertise in complex chemical synthesis is critical for TDF production.

Patent Landscape and Exclusivity

The patent landscape for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate is largely characterized by expired primary patents, allowing for the widespread production and sale of generic versions. However, secondary patents and formulation-specific patents can still influence market dynamics.

Efavirenz Patents

The original patent for Efavirenz (marketed as Sustiva by Bristol-Myers Squibb) expired in many key markets around 2014. This expiration paved the way for generic competition.

Original Compound Patent: Expired in major markets.
Process Patents: Various process patents have been filed and expired, or are nearing expiration. These patents cover specific manufacturing methods, which can be a source of contention in the generic market.
Formulation Patents: Patents related to specific dosage forms or combinations may still be in effect, although less impactful for API supply.

Lamivudine Patents

Lamivudine, originally developed by GlaxoSmithKline (GSK), also has expired compound patents. It is marketed under brand names like Epivir.

Original Compound Patent: Expired in most jurisdictions.
Polymorph Patents: Patents covering different crystalline forms of Lamivudine have been a subject of litigation, potentially affecting the production of specific polymorphic forms.
Manufacturing Patents: Similar to Efavirenz, process patents related to Lamivudine synthesis exist.

Tenofovir Disoproxil Fumarate (TDF) Patents

TDF, a prodrug of tenofovir, was developed by Gilead Sciences (Viread). Its primary patents have also expired, facilitating generic entry. Gilead also developed a successor drug, Tenofovir Alafenamide (TAF), which has its own patent protection.

Original Compound Patent: Expired.
Prodrug/Salt Patents: Patents covering the fumarate salt form and the disoproxil prodrug aspect were significant.
Manufacturing Patents: Specific synthesis routes for TDF are covered by various patents.

Regulatory Approvals and Market Access

Regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) are critical for API manufacturers seeking to supply these drugs for global pharmaceutical formulations.

FDA and EMA Approvals

Manufacturers of Efavirenz, Lamivudine, and TDF APIs must obtain approval for their Drug Master Files (DMFs) from the FDA and comply with EMA regulations for manufacturing sites and APIs. These approvals ensure that the APIs meet stringent quality, safety, and purity standards.

DMF Submissions: Successful DMF submissions to the FDA allow generic drug manufacturers to reference the API supplier's data in their Abbreviated New Drug Applications (ANDAs).
Certificate of Suitability (CEP): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required, demonstrating compliance with European Pharmacopoeia monographs.

WHO Prequalification

The World Health Organization (WHO) Prequalification Program is essential for manufacturers aiming to supply APIs for procurement by UN agencies and global health initiatives, particularly in low- and middle-income countries.

Prequalification Process: WHO prequalification assesses manufacturing sites, quality control systems, and product specifications against international standards.
Impact on Access: WHO prequalification significantly enhances market access for APIs used in essential medicines, fostering competition and driving down prices. Companies like Cipla, Hetero, and Aurobindo have a substantial number of WHO-prequalified APIs.

Generic Drug Approvals

The approval of generic finished drug products that utilize these APIs is directly linked to the quality and regulatory standing of the API supplier. Regulatory scrutiny of impurities, particularly genotoxic impurities, has intensified, requiring robust analytical methods and stringent process controls from API manufacturers.

Supply Chain Dynamics and Risks

The supply chain for these antiretroviral APIs is subject to several factors that can influence availability and pricing. Geopolitical stability, raw material sourcing, manufacturing capacity utilization, and global health emergencies are key considerations.

Raw Material Sourcing

The synthesis of Efavirenz, Lamivudine, and TDF involves multiple chemical intermediates. The availability and cost of these upstream raw materials, often sourced from China and India, directly impact API production costs. Disruptions in the supply of key intermediates can lead to API shortages.

Manufacturing Capacity and Utilization

While significant production capacity exists, actual output can be affected by factors such as:

Demand Fluctuations: Changes in HIV treatment guidelines or the introduction of new antiretroviral regimens can alter demand for these older drugs.
Plant Maintenance and Upgrades: Scheduled or unscheduled downtime for manufacturing facilities can temporarily reduce supply.
Regulatory Compliance Issues: Findings from regulatory inspections can lead to production halts or delays until corrective actions are implemented.

Price Volatility

The prices of these APIs are influenced by:

Competition: The large number of generic manufacturers generally leads to competitive pricing.
Raw Material Costs: Fluctuations in chemical precursor prices.
Volume Discounts: Large-scale procurement by global health organizations can negotiate lower prices.
Geographic Concentration: Reliance on a few key manufacturing hubs can create vulnerabilities to localized disruptions, potentially leading to price spikes.

Geopolitical and Environmental Factors

Trade Policies and Tariffs: Changes in international trade policies can affect the cost of importing raw materials or exporting finished APIs.
Environmental Regulations: Stricter environmental regulations in manufacturing countries can increase production costs or lead to temporary shutdowns if compliance is not met.
Pandemics/Health Crises: As seen with COVID-19, global health crises can disrupt manufacturing, logistics, and the availability of skilled labor, impacting supply chains.

Future Outlook

The demand for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate is expected to remain significant, particularly in resource-limited settings where they are a cornerstone of HIV treatment due to their affordability and efficacy in combination therapies. However, the increasing adoption of newer antiretroviral drugs with improved efficacy and safety profiles (e.g., those based on Tenofovir Alafenamide or integrase inhibitors) may gradually influence long-term demand.

API manufacturers continue to invest in process optimization and capacity expansion to maintain competitive pricing and ensure uninterrupted supply. Ongoing vigilance regarding regulatory compliance, impurity control, and supply chain resilience will be critical for sustained market access.

Key Takeaways

The global supply of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate is dominated by a few major API manufacturers, primarily in India and China.
Expired primary patents have enabled robust generic competition, but secondary patents and regulatory hurdles remain important considerations.
Regulatory approvals from FDA, EMA, and WHO prequalification are critical for market access and global health procurement.
Supply chain risks include raw material availability, manufacturing capacity utilization, price volatility, and geopolitical or environmental disruptions.
Demand is expected to remain strong in developing countries, though newer antiretrovirals may impact long-term market share.

Frequently Asked Questions

What are the primary risks associated with the supply of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate? Risks include the concentration of manufacturing in specific geographic regions (India, China), reliance on upstream intermediate suppliers, potential for regulatory non-compliance impacting production, and susceptibility to global logistics disruptions.
How do patent expiries impact the availability of these APIs? Patent expiries on the active compounds allow multiple manufacturers to produce generic versions of the APIs. This competition generally leads to lower prices and increased availability worldwide. However, process or formulation patents can still create market entry barriers.
Which regulatory bodies are most influential in approving API manufacturers for these drugs? The U.S. Food and Drug Administration (FDA) for the North American market, the European Medicines Agency (EMA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Europe, and the World Health Organization (WHO) through its Prequalification Program for global health procurement are the most influential.
Are there significant quality differences between APIs supplied by different manufacturers? Reputable manufacturers adhere to stringent Good Manufacturing Practices (GMP) and meet pharmacopoeial standards (e.g., USP, EP, IP). Regulatory approvals (DMFs, CEPs, WHO Prequalification) serve as indicators of quality compliance. Differences may arise in impurity profiles, necessitating careful evaluation by finished drug product manufacturers.
What is the trend for demand for these APIs in the next five years? Demand is projected to remain stable or grow moderately, particularly in lower-income countries where they form part of essential, cost-effective HIV treatment regimens. However, the gradual introduction and adoption of newer antiretroviral drugs with improved resistance profiles and fewer side effects may lead to a slow decline in demand in developed markets and potentially in some upper-middle-income countries.

Cited Sources

[1] World Health Organization. (n.d.). WHO Prequalification Programme. Retrieved from https://www.who.int/teams/regulation-quality-and-innovation/medicines/pq-process [2] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from https://www.edqm.eu/en/certificate-suitability-cep [4] Various Pharmaceutical Company Annual Reports and Investor Presentations (e.g., Cipla, Hetero Drugs, Aurobindo Pharma, Viatris). (Data not publicly linked to specific annual reports due to proprietary nature of capacity figures but reflects general industry disclosures). [5] Industry Market Research Reports on Antiretroviral APIs. (Specific report not cited due to reliance on aggregated industry knowledge). [6] Patent databases (e.g., USPTO, EPO, WIPO) for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate. (Specific patent numbers not listed to maintain conciseness, but analysis is based on general patent expiry timelines for these compounds).

Suppliers and packagers for generic pharmaceutical drug: EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE